Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis
Glioblastoma is a life-threatening primary malignant brain tumor with an unfavorable prognosis. Contributing factors to its poor outcome include tumor heterogeneity, low mutational burden, and immunosuppression within the tumor microenvironment. Recognizing these challenges, immunotherapeutic strate...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2466299 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850139871861014528 |
|---|---|
| author | Zhi Long Zhenjie Yi Wei Yan Hongxin Wang |
| author_facet | Zhi Long Zhenjie Yi Wei Yan Hongxin Wang |
| author_sort | Zhi Long |
| collection | DOAJ |
| description | Glioblastoma is a life-threatening primary malignant brain tumor with an unfavorable prognosis. Contributing factors to its poor outcome include tumor heterogeneity, low mutational burden, and immunosuppression within the tumor microenvironment. Recognizing these challenges, immunotherapeutic strategies have emerged as a promising avenue for glioblastoma treatment. Although several dynamic research and scientific trend have increasingly taken pace in the immunotherapeutic approaches to glioblastoma, systematic bibliometric studies on such trends are few. On this note, this study explores a bibliometric analysis of the research hotspots and trends in glioblastoma immunotherapy. We conducted a search in the Web of Science Core Collection database for articles on glioblastoma immunotherapy published between 2004 and 2024. Using VOSviewer and CiteSpace software, we analyzed collected articles to explore aspects such as country of origin, journal of publication, affiliated institute, authorship, keywords, and citation patterns. As of May 1, 2024, we retrieved 3,729 papers on Glioblastoma Immunotherapy. In the field of glioblastoma immunotherapy, the United States stands out as the leading contributor, with 1,708 publications and a substantial 90,590 citations. Following closely, China has made significant contributions through 926 publications, earning 17,533 citations, while Germany adds to the body of knowledge with 349 publications and 16,355 citations. Furthermore, Authoritative journals in this field include Clinical Cancer Research and Neuro-Oncology. The top five keywords during this period were temozolomide, radiotherapy, dendritic cell, cytotoxic T lymphocyte, and vaccination. Moreover, Hotspots in the field include immune checkpoint inhibitors and chimeric antigen receptor T cell therapy. |
| format | Article |
| id | doaj-art-bd0040ce04e747b2931003c1479782e2 |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-bd0040ce04e747b2931003c1479782e22025-08-20T02:30:05ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2466299Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysisZhi Long0Zhenjie Yi1Wei Yan2Hongxin Wang3Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, ChinaThe First Department of General Surgery, Hunan Provincial People’s Hospital, Hunan Normal University, Changsha, ChinaDepartment of Neurosurgery, The Affiliated Changsha Central Hospital, Hengyang Medical School，University of South China, Changsha, ChinaGlioblastoma is a life-threatening primary malignant brain tumor with an unfavorable prognosis. Contributing factors to its poor outcome include tumor heterogeneity, low mutational burden, and immunosuppression within the tumor microenvironment. Recognizing these challenges, immunotherapeutic strategies have emerged as a promising avenue for glioblastoma treatment. Although several dynamic research and scientific trend have increasingly taken pace in the immunotherapeutic approaches to glioblastoma, systematic bibliometric studies on such trends are few. On this note, this study explores a bibliometric analysis of the research hotspots and trends in glioblastoma immunotherapy. We conducted a search in the Web of Science Core Collection database for articles on glioblastoma immunotherapy published between 2004 and 2024. Using VOSviewer and CiteSpace software, we analyzed collected articles to explore aspects such as country of origin, journal of publication, affiliated institute, authorship, keywords, and citation patterns. As of May 1, 2024, we retrieved 3,729 papers on Glioblastoma Immunotherapy. In the field of glioblastoma immunotherapy, the United States stands out as the leading contributor, with 1,708 publications and a substantial 90,590 citations. Following closely, China has made significant contributions through 926 publications, earning 17,533 citations, while Germany adds to the body of knowledge with 349 publications and 16,355 citations. Furthermore, Authoritative journals in this field include Clinical Cancer Research and Neuro-Oncology. The top five keywords during this period were temozolomide, radiotherapy, dendritic cell, cytotoxic T lymphocyte, and vaccination. Moreover, Hotspots in the field include immune checkpoint inhibitors and chimeric antigen receptor T cell therapy.https://www.tandfonline.com/doi/10.1080/21645515.2025.2466299Bibliometric analysisglioblastomaimmunotherapyVOSviewerCiteSpace |
| spellingShingle | Zhi Long Zhenjie Yi Wei Yan Hongxin Wang Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis Human Vaccines & Immunotherapeutics Bibliometric analysis glioblastoma immunotherapy VOSviewer CiteSpace |
| title | Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis |
| title_full | Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis |
| title_fullStr | Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis |
| title_full_unstemmed | Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis |
| title_short | Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis |
| title_sort | trends in the immunotherapy for glioblastoma a two decade bibliometric analysis |
| topic | Bibliometric analysis glioblastoma immunotherapy VOSviewer CiteSpace |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2025.2466299 |
| work_keys_str_mv | AT zhilong trendsintheimmunotherapyforglioblastomaatwodecadebibliometricanalysis AT zhenjieyi trendsintheimmunotherapyforglioblastomaatwodecadebibliometricanalysis AT weiyan trendsintheimmunotherapyforglioblastomaatwodecadebibliometricanalysis AT hongxinwang trendsintheimmunotherapyforglioblastomaatwodecadebibliometricanalysis |